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The pyridocarbazole alkaloid ellipticine1) 1 is well known
for its high cytotoxicity against several cancer cell lines due
to its intercalating properties and its ability to inhibit DNA
religation by topoisomerase II.2,3) A number of angular
analogs have been prepared in order to obtain more active
compounds. For example, one of the most promising prod-
ucts appeared to be intoplicine 2, synthesised firstly by
Nguyen et al.,4) which acts both as an intercalating agent and
as a topoisomerase I and II inhibitor.5,6)
So, considering the cytototoxic properties of angular ni-
trogenous heterocycles, other groups have elaborated several
angular tetracyclic compounds derived from two or three ni-
trogenous heterocycles. Dalla Via et al.7) prepared indolo-
naphtyridines 3 carrying a dialkylaminoalkyl side chain and
different substituents. Linear flow dichroism studies demon-
strated these compounds were able to intercalate into DNA
and in vitro cytotoxicity studies showed IC50 on HL-60 cells
varying between 0.5 and 1.6 mM. Furthermore, Da Settimo et
al.8) prepared several derivatives of purinoquinazoline 4,
pyridopyrimidopurine and pyridopyrimidobenzimidazole, all
of them carrying a dialkylaminoalkyl side chain. Only puri-
noquinazolines could bind strongly to DNA and therefore
could induce DNA double-strand breaks via inhibition of
DNA religation by topoisomerase II. These compounds
showed IC50 on HL-60 cells varying between 0.072 and
0.47 mM. Chart 1 represents some of the structures men-
tionned above.
Therefore, as a part of our studies related to the pharmaco-
chemistry of angular polynitrogenous tetracycles,9,10) we ini-
tiated a program in order to examine the synthesis of new
pyridopyrroloquinolines and their antitumor activities against
resistant cell lines (MDR phenotype ). Our synthetic
methodology resides in the use of enaminones 5 derived
from quinolines and cyclopentane-1,3-dione. Key steps of
the synthesis are the photocyclisation of such enaminones
followed by Beckmann rearrangement to afford hydroxypyri-
dine ring from 2-cyclopent-1-one ring, as shown in Chart 2.
In this context, we have previously described the synthesis of
indoloquinolines and pyridocarbazoles by photocyclisation
of enaminones derived from 3 or 6-aminoquinoline and cy-
clohexane-1,3-dione.11,12) This present work will allow us to
study the photoreactivity of new enaminones and to elaborate
potentially cytotoxic compounds.
Results and Discussion
Chemistry Firstly, we studied the reactivity of sec-
ondary halogenated enaminones 12 and 13. As shown in
Chart 3, these compounds were obtained in two steps by con-
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densation of 3 or 6-aminoquinoline (8a, b) with cyclopen-
tane-1,3-dione in toluene with paratoluenesulfonic acid, fol-
lowed by a-iodination of 10 and 11 using BTMAICl2, ac-
cording to the procedures previously described.11,13)
Irradiation of enaminones 12 and 13 in acetonitrile with or
without triethylamine gave a mixture of starting product and
dehalogenated product, as shown in Table 1. Contrary to a-
iodinated enaminones derived from 3 or 6-aminoquinoline
and cyclohexane-1,3-dione, no cyclisation occurred.11)
Another attempt at photocyclisation was conducted ac-
cording to the one-pot synthesis of pyridocarbazole and in-
doloquinoline previously described.11) Compounds 10 and 11
were irradiated in acetonitrile / triethylamine in presence
of iodine (2 eq) for 4 h. But only iodinated products 12 and
13 were obtained without any cyclised products, as shown in
Table 2. So, when iodinated enaminones derived from
aminoquinolines and cyclopentane-1,3-dione undergo irradi-
ation, the competition between dehalogenation and cyclisa-
tion13) is clearly in favour of dehalogenation. As expected,
this dehalogenation is enhanced by the presence of triethyl-
amine, particularly in the case of 6-aminoquinoline deriva-
tives. Chart 3 recapitulates these attempts.
Since secondary halogenated enaminones didn’t undergo
photocyclisation, the reactivity of tertiary enaminones 14 and
15 was investigated (Chart 4). Previous works have been con-
ducted by Gardette et al.14) who cyclised enaminones derived
from N-methylaniline and cyclopentan-1,3-dione. These
compounds were prepared by N-methylation of enaminones
10 and 11 using methyl iodide in toluene in presence of
sodium hydride. Irradiation of such compounds under differ-
ent conditions, as shown in Table 3, produced the best yield
for cyclised compounds 16 and 17 when a mixture
toluene/methanol (95/5) in a quartz reactor was being used,
proving thus that photocyclisation requires much energy. The
position of the intracyclic nitrogen atom seems to influence
the reactivity of these compounds because photocyclisation
yield is two fold smaller in the case of compound 15, derived
from 6-aminoquinoline.
This photocyclisation appears to be regioselective, since
we obtain only angular derivatives. The angular structure of
these compounds is proven by the multiplet corresponding to
H1, and whose shift in 1H-NMR spectrum appears at
8.77 ppm for compound 16 and 9.17 ppm for compound 17,
due to the deshielding effect of the carbonyl group. Besides,
compound 16 shows a characteristic singlet corresponding to
H6 at 8.76 ppm and compound 17 shows a characteristic AB
system corresponding to H5 and H6 at 7.57 ppm.
Thus, the cyclopentenone ring has been modified in three
steps including Beckmann rearrrangement in order both to
introduce a third nitrogen atom and to obtain some totally
aromatised compounds which can theoretically better inter-
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Table 1. Irradiation of Enaminones 12 and 13
Enaminone
Irradiation 
Starting material
Dehalogenated 
conditions product
12 CH3CN, Et3N, 4 h 00 12; 0% 10; 80%
CH3CN, 4 h 00 12; 80% 10; 20%
13 CH3CN, Et3N, 4 h 00 13; 0% 11; 95%
CH3CN, 4 h 00 13; 100% 11; 0%
Table 2. Irradiation of Enaminones 10 and 11
Enaminone
Irradiation 
Starting material
Halogenated 
conditions product
10 CH3CN, I2, Et3N, 4 h 00 10; 40% 12; 40%
CH3CN, I2, 4 h 00 10; 40% 12; 60%
11 CH3CN, Et3N, I2, 4 h 00 11; 20% 13; 80%
CH3CN, I2, 4 h 00 11; 0% 13; 100%
Table 3. Irradiation of Enaminones 14 and 15
Enaminone Irradiation conditions Cyclised product
14 Pyrex, MeOH, 4 h 00 16; 20%
Pyrex, toluene/MeOH (50/50), 4 h 00 16; 30%
Pyrex, toluene/MeOH (95/5), 4 h 00 16; 45%
Quartz, toluene/MeOH (95/5), 4 h 00 16; 50%
15 Pyrex, MeOH, 4 h 00 17; 5%
Pyrex, toluene/MeOH (50/50), 4 h 00 17; 5%
Pyrex, toluene/MeOH (95/5), 4 h 00 17; 15%
Quartz, toluene/MeOH (95/5), 4 h 00 17; 25%
Chart 3
Chart 4
Chart 5
calate into DNA.
First of all, the compounds 16 and 17 were treated by hy-
droxylamine hydrochloride, following the procedure de-
scribed by Sekar et al.15) and Z oximes 18 and 19 were ob-
tained. Configuration of CN bond was determined by con-
sidering the 13C-NMR shift of the secondary carbon adjacent
to the oxime function in our structures and in close com-
pounds 20 and 21 synthetised by Scheiber et al.,16) as shown
in Chart 5.
The second step of this ring modification consisted in re-
gioselective Beckmann rearrangement17) using polyphos-
phoric acid PPA, which gave lactams 22 (30%) and 23
(60%). The structure of the lactams was deduced from the
configuration of the oximes, considering the mechanism of
Beckmann transposition, and was confirmed by considering
the 13C-NMR shift of the secondary carbon adjacent to the
amide function in our structures and in close compounds 24
and 25 synthetised by Scheiber et al.,16) as shown in Chart 6.
In order to obtain compounds 22 and 23 with better yields,
compounds 16 and 17 were submitted to Schmidt transposi-
tion17) using sodium azide in refluxing sulfuric acid. But after
3 h, the starting material was recovered unchanged.
Finally, compounds 22 and 23 were treated by
palladium/carbon 10% in diphenylether18) and underwent
C8–C9 bond oxydation to give the pyridopyrroloquinolines 26
and 27 with 30% and 32% yield respectively, as shown in
Chart 7. This oxydation was expected to be more successful
than previous attempts to oxydize cyclohexenone ring, since
lactime tautomer in d-lactam ring is probably more easely
formed than enol tautomer in cyclohexenone ring.
Biological Results In continuation of our previous
works9,10) concerning the antiproliferative activity of tetra-
cyclic nitrogenous heterocycles, and more precisely, their ac-
tivity against MDR cancer cells lines, the cytotoxicity of the
compounds 16, 17, 22, 23, 26 and 27 was evaluated by a cell
growth inhibition assay against two human cell lines: K 562
(leukemia), and A 2780 (ovarian cancer) doxorubicine-sensi-
tive and resistant (MDR) and was compared to the cytotoxi-
city of doxorubicine. The resistant subline A 2780 R was es-
tablished by the continuous exposure of cells to gradually in-
creasing concentrations of doxorubicine. The resistant sub-
line K 562 R wasn’t tested because of the poor activity of our
products against K 562 S cells. IC50 (concentration inhibiting
50% of the cell proliferation) expressed in mol/l and resis-
tance factor (IC50 on A2780 resistant cells/IC50 on A2780
sensitive cells) of each compound are recapitulated in Table
4. IC50 of compound 22 couldn’t be determined exactly be-
cause of its poor solubility in the culture medium.
All the compounds were less effective than doxorubicine
in all sensitive cells, whereas compounds 17, 23, 26 and 27
were as active as doxorubicine on A 2780 resistant cells with
IC50 varying between 5 and 9.810
6 mol/l. The resistance
factor of all those compounds (except 22, not determined)
varies between 1.1 and 6.1 (doxorubicine: 121), which indi-
cates that these compounds are not concerned by the mul-
tidrug resistance phenomenon.
Among these compounds, the less active ones are those
which possess d-lactam ring. This can be due either to the
poor solubility of these structures in the culture medium or to
the structure of the compound itself. Besides, compounds de-
rived from 6-aminoquinoline are globally more active than
compounds derived from 3-aminoquinoline, proving the im-
portance of the quinolinic nitrogen position in biological ac-
tivity. But there’s only a little difference between the com-
pounds 16 and 17 carring a cyclopentenone ring and the
compounds 26 and 27 carrying an hydroxypyridine ring.
Compounds 16, 17, 26 and 27, which show the lowest
IC50, are good candidates for further in vivo studies.
Conclusion
In this paper, we have reported the synthesis of tetracyclic
nitrogen heterocycles: pyrido pyrroloquinolines obtained
from cyclopentanopyrroloquinolines via a Beckmann re-
arrangement. The photochemical step which gives cyclopen-
tanopyrroloquinolines from enaminones occured with a total
regioselectivity, since only angular compounds are obtained.
The first in vitro studies reveal that the main interest of these
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Chart 6 Chart 7
Table 4. IC50 and Resistance Factor of Tested Compounds and Doxorubicine
Compounds K 562 cells (mol/l) A 2780 cells sensitive (mol/l) A 2780 cells resistant (mol/l) Resistance factor
16 4.91051.1105 3.31052.5105 8.81055.4105 2.6
17 5.81051.2105 2.71061.5106 6.31065.6107 2.3
22 4.2104 4.2104 4.2104 n.d.
23 7.71051.9105 1.61057106 9.81069.4107 6.1
26 51051105 4.51061107 51066107 1.1
27 1.11058.3106 5.71067107 8.51063.8107 1.5
Doxorubicine 1.61073.3108 2.41084109 2.91064.9107 121
compounds resides in their activity toward resistant cells.
Further studies on the pharmacomodulation of such com-
pounds are now in progress and should lead to an interesting
class of new potential anticancer agents with no multidrug
resistance phenomena.
Experimental
IR spectra were recorded with a Perkin–Elmer 377 spectrophotometer.
Absorption bands are expressed in centimeters (cm1) using polystyrene cal-
ibration and only noteworthy absorptions are listed. 1H- and 13C-NMR spec-
tra were recorded on a Brüker AC 100 or EM 400 WB. Chemical shift data
are reported in ppm downfield d from TMS. Coupling constants J are given
in Hz. s, d, dd, t, and m mean respectively singlet, doublet, double doublet,
triplet, and multiplet. Mass spectrometry was done on a LKB 2091 instru-
ment at 15 eV. Melting points were determined on a Buchi capillary melting
point apparatus and are not corrected. Elemental analysis was performed by
Microanalytical center, ENSCM, Montpellier.
Irradiations were conducted in a pyrex or a quartz well apparatus using a
medium pressure mercury UV lamp (Heraeus TQ 150). Total volume of sol-
vent(s) was about 350—400 ml. In order to remove oxygen, the reaction
mixture was submitted to ultrasound waves for 10 min before irradiation.
Besides, during the irradiation, the reaction mixture was flushed with a
stream of nitrogen. Triethylamine (4 ml) or molecular iodine (500 mg,
1.97 mmol) could be added to the reaction mixture.
3-[3-Quinolinylamino]cyclopent-2-en-1-one 10 A solution of 3-
aminoquinoline (3 g, 21 mmol), 1.3 cyclohexanedione (2.2 g, 22 mmol) and
paratoluenesulfonic acid (500 mg, 2.9 mmol) in 50 ml of anhydrous tolu-
ene was refluxed under nitrogen in a Dean–Stark apparatus for 6 h. After
cooling, the solution was washed with water and extracted with
dichloromethane. Organic layers were dried over sodium sulfate and evapo-
rated in vacuo. The crude product was chromatographed on alumina gel
using dichloromethane and a gradient of methanol as eluent to give 10 as a
yellow powder: 40%, mp: 130—132 °C. 1H-NMR (CDCl3, 100 MHz) d :
2.44 (2H, m, H5), 2.80 (2H, m, H4), 5.68 (1H, s, H2), 7.62 (3H, m, H5, H6
and H7), 7.90 (2H, m, H4 and H8), 8.57 (1H, d, J2.2 Hz, H2); 13C-
NMR (CDCl3, 100 MHz) d : 29.19, 33.41, 102.86, 124.88, 127.78, 128.14,
128.47 (2C), 129.28, 134.21, 144.73, 145.39, 174.58, 208.34. Anal. Calcd
for C14H12N2O: C, 75.0; H, 5.36; N, 12.50. Found: C, 74.96; H, 5.32; N,
12.39.
3-[6-Quinolinylamino]cyclopent-2-en-1-one 11 This compound was
obtained in 25% yield according to the procedure described for compound
10. White powder, mp: 134—136 °C. 1H-NMR (CDCl3, 100 MHz) d : 2.39
(2H, m, H5), 2.76 (2H, m, H4), 5.67 (1H, s, H2), 7.31 (2H, m, H7 and H3),
7.49 (1H, s, H5), 7.98 (2H, m, H4 and H8), 8.69 (1H, m, H2); 13C-NMR
(CDCl3, 100 MHz) d : 29.3, 33.4, 102.8, 116.8, 122.2, 124.9, 129.2, 130.0,
136.5, 138.6, 145.1, 149.4, 174.2, 208.1. Anal. Calcd for C14H12N2O: C,
75.0; H, 5.36; N, 12.50. Found: C, 75.04; H, 5.48; N, 12.42.
2-Iodo-3-[3-quinolinylamino]cyclopent-2-en-1-one 12 A solution of
enaminone 10 (250 mg, 1.1 mmol), benzyltrimethylammonium dichloroio-
date BTMAICl2 (390 mg, 1.1 mmol) and sodium bicarbonate (660 mg,
7.7 mmol) in 40 ml of anhydrous dichloromethane and 20 ml of anhydrous
methanol was stirred under nitrogen at room temperature for 1 h. The solu-
tion was filtered to eliminate sodium bicarbonate and the solvents were
evaporated in vacuo. The residue was dissolved in dichloromethane and
washed with water. The organic layer was dried over sodium sulfate and
evaporated in vacuo. The crude product was chromatographed on alumina
gel using dichloromethane and a gradient of methanol as eluent to give 12 as
a yellow powder: 80%, mp: 104—106 °C. 1H-NMR (CDCl3, 100 MHz) d :
2.53 (2H, m, H5), 2.82 (2H, m, H4), 7.53 (1H, m, H7), 7.67 (1H, m, H6),
7.76 (1H, d, J8.1 Hz, H5), 7.99 (2H, m, H4 and H8), 8.70 (1H, d,
J2.5 Hz, H2); 13C-NMR (CDCl3, 100 MHz) d : 29.1, 32.6, 70.7, 128.3
(2C), 128.7 (2C), 129.1, 130.6, 130.7, 146.2, 147.8, 175.5, 200.6. Anal.
Calcd for C14H11IN2O: C, 48.0; H, 3.14; N, 8.0. Found: C, 47.88; H, 3.17; N,
7.96.
2-Iodo-3-[6-quinolinylamino]cyclopent-2-en-1-one 13 This com-
pound was obtained in 80% yield according to the procedure described for
compound 12. Yellow powder, mp: 110—112 °C. 1H-NMR (CDCl3,
100 MHz) d : 2.62 (2H, m, H5), 2.96 (2H, m, H4), 7.46 (1H, m, H3), 7.57
(1H, d, J6.5 Hz, H7), 7.65 (1H, s, H5), 8.1 (1H, d, J4.4 Hz, H4), 8.16
(1H, d, J8.2 Hz, H8), 8.85 (1H, d, J3.0 Hz, H2); 13C-NMR (CDCl3,
100 MHz) d : 28.8, 32.6, 70.9, 121.1, 122.6, 126.9, 129.0, 130.9, 136.2,
136.7, 146.1, 150.6, 174.7, 199.8. Anal. Calcd for C14H11IN2O: C, 48.0; H,
3.14; N, 8.0. Found: C, 47.97; H, 3.25; N, 8.11.
3-[(3-Quinolinyl)methylamino]cyclopent-2-en-1-one 14 Compound
10 (600 mg, 2.7 mmol) was added to a suspension of sodium hydride (1 g,
25 mmol, 60% in mineral oil) in anhydrous toluene (50 ml). The mixture was
refluxed under nitrogen for 2 h and cooled to room temperature. Methyl io-
dide (5 ml, 80 mmol) was then added and the mixture was refluxed for 4 h.
After cooling, toluene was washed with water and the insoluble residue in
the balloon flask was dissolved in dichloromethane and also washed with
water. The organic layers were dried over sodium sulfate and evaporated in
vacuo. The crude product was chromatographed on alumina gel with
dichloromethane and a gradient of methanol as eluent to give 14 as a yellow
oil: 60%. 1H-NMR (CDCl3, 100 MHz) d : 2.36 (2H, m, H5), 2.50 (2H, m,
H4), 3.41 (3H, s, CH3), 5.16 (1H, s, H2), 7.56 (1H, m, H7), 7.71 (1H, m,
H6), 7.78 (1H, d, J8.1 Hz, H5), 7.99 (1H, d, J2.4 Hz, H4), 8.07 (1H, d,
J8.4 Hz, H8), 8.76 (1H, d, J2.5 Hz, H2); 13C-NMR (CDCl3, 100 MHz)
d : 28.8, 34.8, 41.8, 103.9, 128.1, 128.1, 128.1, 129.7, 130.5, 132.4, 138.5,
147.1, 149.1, 177.3, 204.7. Anal. Calcd for C15H14N2O: C, 75.63; H, 5.88;
N, 11.76. Found: C, 75.75; H, 5.82; N, 11.81.
3-[(6-Quinolinyl)methylamino]cyclopent-2-en-1-one 15 This com-
pound was obtained in 60% yield according to the procedure described for
compound 14. Yellow oil. 1H-NMR (CDCl3, 100 MHz) d : 2.41 (2H, m, H5),
2.56 (2H, m, H4), 3.44 (3H, s, CH3), 5.21 (1H, s, H2), 7.46 (1H, m, H3),
7.57 (1H, d, J6.5 Hz, H7), 7.67 (1H, s, H5), 8.15 (2H, m, H4 and H8),
8.95 (1H, d, J2.6 Hz, H2); 13C-NMR (CDCl3, 100 MHz) d : 30.1, 34.6,
41.7, 103.6, 122.4, 124.6, 128.2, 128.8, 131.8, 136.3, 143.1, 147.3, 151.5,
177.3, 204.7. Anal. Calcd for C15H14N2O: C, 75.63; H, 5.88; N, 11.76.
Found: C, 75.60; H, 5.81; N, 11.72.
7-Methyl-10-oxocyclopentano[4,5]pyrrolo[2,3-c]quinoline 16 Com-
pound 14 (500 mg, 2.1 mmol) underwent irradiation under different condi-
tions (see Table 3). Then, the solvents were evaporated under reduced pres-
sure. The crude product was chromatographed on alumina gel using
dichloromethane as eluent to give 16 as a white powder: 50% (best yield),
mp: 213—215 °C. 1H-NMR (CDCl3, 100 MHz) d : 2.86 (2H, m, H9), 2.95
(2H, m, H8), 3.63 (3H, s, CH3), 7.60 (2H, m, H2 and H3), 8.10 (1H, m, H4),
8.76 (2H, m, H1 and H6); 13C-NMR (CDCl3, 100 MHz) d : 20.1, 31.4, 41.3,
121.1, 123.3, 124.2, 127.2, 127.6, 128.2, 129.1, 135.5, 135.6, 143.7, 167.9,
195.3. IR cm1nCO1674. Anal. Calcd for C15H12N2O: C, 76.27; H,
5.08; N, 11.86. Found: C, 76.16; H, 5.11; N, 11.91.
7-Methyl-10-oxocyclopentano[4,5]pyrrolo[3,2-f ]quinoline 17 This
compound was obtained in 25% yield (best yield) according to the proce-
dure described for compound 16. White powder, mp: 206—208 °C. 1H-
NMR (CDCl3, 100 MHz) d : 2.71 (2H, m, H9), 2.81 (2H, m, H8), 3.42 (3H,
s, CH3), 7.36 (1H, d, J9.1 Hz, H6), 7.41 (1H, m, H2), 7.78 (1H, d,
J9.1 Hz, H5), 8.79 (1H, s, H3), 9.17 (1H, dd, J7.1, 1.22 Hz, H1); 13C-
NMR (CDCl3, 100 MHz) d : 21.3, 31.2, 41.4, 114.7, 119.9, 121.7, 121.8,
123.8, 125.8, 136.1, 139.3, 145.8, 149.2, 166.5, 195.7. IR cm1
nCO1667. Anal. Calcd for C15H12N2O: C, 76.27; H, 5.08; N, 11.86.
Found: C, 76.32; H, 5.06; N, 11.80.
10-Hydroxyimino-7-methyl-cyclopentano[4,5]pyrrolo[2,3-c]quinoline
18 Compound 16 (180 mg, 0.76 mmol) and hydroxylamine hydrochloride
(1 g, 14.4 mmol) were dissolved in absolute ethanol (15 ml) and 2 ml of pyri-
dine were added. The reaction mixture was refluxed under nitrogen for 3 h.
After cooling, 30 ml of an aqueous solution of sodium carbonate10% were
added. After extraction with dichloromethane, the organic layers were dried
over sodium sulfate and evaporated in vacuo. The crude product was chro-
matographed on silica gel using dichloromethane and a gradient of methanol
as eluent to give 18 as a white powder: 30%, mp: 154—156 °C. 1H-NMR
(CDCl3, 400 MHz) d : 2.99 (2H, m, H9), 3.32 (2H, m, H8), 3.81 (3H, s,
CH3), 7.52 (2H, m, H2 and H3), 8.0 (1H, d, J8.0 Hz, H4), 8.78 (1H, s,
H6), 8.98 (1H, d, J8.0 Hz, H1); 13C-NMR (CDCl3, 400 MHz) d : 22.6,
31.2, 31.7, 116.9, 123.7, 123.7, 126.5, 127.4, 127.5, 128.2, 135.1, 135.6,
143.2, 158.0, 158.3. IR cm1nCN1584, nO–H2400—3600, MS252
(35%), 251 (20%), 154 (100%), 136 (80%). Anal. Calcd for C15H13N3O: C,
71.71; H, 5.18; N, 16.73. Found: C, 71.83; H, 5.21; N, 16.67.
10-Hydroxyimino-7-methyl-cyclopentano[4,5]pyrrolo[3,2-f]quinoline
19 This compound was obtained in 33% yield according to the procedure
described for compound 18. White powder, mp: 155—157 °C. 1H-NMR
(CDCl3, 400 MHz) d: 3.09 (2H, m, H9), 3.27 (2H, m, H8), 3.85 (3H, s,
CH3), 7.75 (1H, d, J9.1 Hz, H6), 7.85 (1H, m, H2), 8.15 (1H, d, J9.1 Hz ,
H5), 8.85 (1H, d, J5.4 Hz, H3), 10.07 (1H, d, J8.3 Hz, H1); 13C-NMR
(CDCl3, 400 MHz) d : 24.2, 31.5, 31.7, 113.9, 117.3, 118.6, 121.3, 121.8,
125.6, 136.6, 139.9, 141.7, 145.8, 158.1, 159.01. IR cm1nCN1586,
nO–H2400—3600, MS252 (5%), 250 (6%), 154 (40%), 149 (100%), 136
(40%). Anal. Calcd for C15H13N3O: C, 71.71; H, 5.18; N, 16.73. Found: C,
71.63; H, 5.20; N, 16.69.
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8,9-Dihydro-7-methyl-11-oxopyrido[3,4-4,5]pyrrolo[2,3-c]quinoline
22 Compound 18 (80 mg, 0.32 mmol) was added to polyphosphoric acid
PPA (3 g) and phosphorus pentoxide (2 g) and the reaction mixture was
stirred at 130 °C for 1 h. After cooling, 100 ml of ice cooled water were
added. Then, sodium carbonate was added until pH became 7. After extrac-
tion with dichloromethane, the organic layers were dried over sodium sulfate
and evaporated in vacuo. The crude product was chromatographed on silica
gel using dichloromethane and a gradient of methanol as eluent to give 22 as
a white powder: 30%, mp: 184—186 °C. 1H-NMR (CDCl3, 400 MHz) d :
3.37 (2H, t, J7.0 Hz, H8), 3.94 (2H, t, J7.0 Hz, H9), 4.14 (3H, s, CH3),
7.97 (2H, m, H2 and H3), 8.23 (1H, d, J8.1 Hz, H4), 9.50 (1H, s, H6), 9.78
(1H, d, J8.4 Hz, H1); 13C-NMR (CDCl3, 400 MHz) d : 22.3, 32.1, 39.7,
109.02, 120.8, 122.3, 129.6, 129.9, 130.0 (2C), 132.4, 133.5, 134.2, 156.1,
167.0. IR cm1nCO1645, MS252 (18%), 154 (96%), 136 (100%).
Anal. Calcd for C15H13N3O: C, 71.71; H, 5.18; N, 16.73. Found: C, 71.79; H,
5.22; N, 16.79.
8,9-Dihydro-7-methyl-11-oxo-pyrido[3,4-4,5]pyrrolo[3,2-f ]quinoline
23 This compound was obtained in 60% yield according to the procedure
described for compound 22. White powder, mp: 198—200 °C. 1H-NMR
(CDCl3, 400 MHz) d : 3.29 (2H, t, J7.1 Hz, H8), 3.89 (2H, t, J7.1 Hz,
H9), 4.02 (3H, s, CH3), 7.98 (1H, m, H2), 8.16 (1H, d, J9.2 Hz, H6), 8.26
(1H, d, J9.2 Hz, H5), 8.98 (1H, d, J5.0 Hz, H3), 10.81 (1H, d, J8.5 Hz,
H1); 13C-NMR (CDCl3, 400 MHz) d : 21.9, 31.4, 40.2, 107.8, 116.3, 120.2,
120.3, 121.1, 124.7, 135.5, 136.5, 140.9, 147.3, 148.3, 168.1. IR
cm1nCO1639, MS252 (6%), 250 (3%), 154 (100%), 149 (60%), 136
(85%). Anal. Calcd for C15H13N3O: C, 71.71; H, 5.18; N, 16.73. Found: C,
71.59; H, 5.13; N, 16.68.
11-Hydroxy-7-methyl-pyrido[3,4-4,5]pyrrolo[2,3-c]quinoline 26
Compound 22 (40 mg, 0.16 mmol) was added to a supension of Pd/carbon
10% (100 mg) in diphenylether (20 ml) and the reaction mixture was re-
fluxed under nitrogen for 1 h. Still hot, the reaction mixture was filtered in
order to eliminate Pd/carbon, which was washed with a hot mixture of
dichloromethane and methanol (50/50). Dichloromethane and methanol
were evaporated in vacuo and the diphenylether containing the final product
was chromatographed on silica gel using dichloromethane as eluent to elimi-
nate diphenylether and dichloromethane and a gradient of methanol to give
26 as a yellow oil: 30%. 1H-NMR (CDCl3, 400 MHz) d : 4.01 (3H, s, CH3),
6.91 (1H, d, J7.1 Hz, H8), 7.77 (1H, d, J6.9 Hz, H9), 7.90 (2H, m, H2
and H3), 8.18 (1H, d, J8.0 Hz, H4), 9.43 (1H, s, H6), 10.1 (1H, d,
J8.4 Hz, H1); 13C-NMR (CDCl3, 400 MHz) d : 31.2, 96.6, 110.5, 119.0,
120.1, 123.5, 129.3, 129.8, 130.6, 131.4, 132.8, 133.3, 134.2, 136.7, 152.20.
IR cm1nO–H2800—3600, MS250 (100%), 176 (30%), 154 (35%),
136 (34%). Anal. Calcd for C15H11N3O: C, 72.29; H, 4.42; N, 16.87. Found:
C, 72.39; H, 4.44; N, 16.87.
11-Hydroxy-7-methyl-pyrido[3,4-4,5]pyrrolo[3,2-f ]quinoline 27
This compound was obtained in 32% yield according to the procedure de-
scribed for compound 26. Yellow oil. 1H-NMR (CDCl3, 400 MHz) d : 3.87
(s, 3H, CH3), 6.54 (d, 1H, J7.1 Hz, H8), 7.27 (d, 1H, J7.1 Hz, H9), 7.5
(m, 2H, H2 and H3), 7.76 (d, 1H, J9.1 Hz, H6), 8.0 (d, 1H, J9.1 Hz, H5),
8.74 (m, 1H, H1); 13C-NMR (CDCl3, 400 MHz) d : 30.3, 94.3, 114.1, 119.3,
121.2, 124.9, 126.7, 127.2, 130.8, 131.4, 136.0, 138.0, 145.2, 146.0, 147.7.
IR cm1nO–H2800—3600, MS250 (100%), 176 (40%), 154 (65%),
136 (45%). Anal. Calcd for C15H11N3O: C, 72.29; H, 4.42; N, 16.87. Found:
C, 72.38; H, 4.46; N, 16.91.
Biological Assay Doxorubicine hydrochloride (Pharmacia, St-Quentin
en Yvelines, France), RPMI 1640 medium and fetal calf serum (Polylabo,
Paris, France) were used in this study. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was provided by Sigma (St-Quentin
Fallavier, France). All other reagents were of analytical grade and were ob-
tained from commercial sources.
Cells and Culture: The human leukemic cell line K 562 was obtained
from the American type culture collection (Rockville, MD, U.S.A.). The
human ovarian carcinoma cell line A 2780 was generously given by Dr P.
Canal (Centre Claudius Regaud, Toulouse). The doxorubicine resistant cell
line A 2780 R was established by the continuous exposure of cells to gradu-
ally increasing concentrations of doxorubicine and was maintained in a
medium supplemented with doxorubicin at 0.1 mg/ml. The MDR phenotype
expression of A 2780 R cell lines was assessed by an immunohistochemistry
method, using the two P-glycoprotein specific murine monoclonal antibody
C219 (Cantocor, Malvern, PA, U.S.A.) and JSB1 (Tebu, Le Perray en Yve-
lines, France). Cultures were grown in RPMI 1460 medium supplemented
with 10% fetal calf serum, antibiotics and glutamine at 37 °C in a humidified
atmosphere containing 5% CO2.
Cytotoxicity Assay: In all the experiments, K 562 and A 2780 cells were
seeded at a final density of 5000 cells/well in 96 well microtiter plates and
were treated with drugs (doxorubicine and compound 16, 17, 22, 23, 26,
27). Seven dilutions were used for each drug. After 96 h of incubation, 10 m l
of MTT solution in PBS (5 mg/ml, Phosphate-buffer saline pH 7.3) were
added to each well and the wells were exposed to 37 °C for 4 h. This colori-
metric assay is based on the ability of live and metabolically unimpaired
tumor-cell targets to reduce MTT to a blue formazan product. Then, 100 m l
of a mixture of isopropanol and 1 M hydrochloric acid (96/4, v/v) were added
to each well. After 10 min of vigourous shaking so as to solubilize formazan
crystals, the absorbance was measured on a microculture plate reader (Dy-
natech MR 5000, France) at 570 nm. For each assay, at least three experi-
ments were performed in triplicate. The resistance factor was calculated
from the ratio between the IC50% growth-inhibitory concentrations (IC50 val-
ues) recorded from A 2780 R and A 2780 S cells, respectively, for the fol-
lowing tested drugs: doxorubicine, compounds 16, 17, 23, 26, 27.
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